Can Patents Deter Innovation? The. Anticommons in Biomedical Research The tragedy of the anticommons is the underuse of a scare resource because the. Can patents deter innovation?: An empirical analysis of the anti-commons effect in the academic biomedical research in Milan Paperback – January 16, Heller and Eisenberg are reacting, in large part, to the growth of patenting within in biomedical science (see Murray () for more detail on.

Author: Tojataxe Shacage
Country: Sao Tome and Principe
Language: English (Spanish)
Genre: Technology
Published (Last): 15 June 2012
Pages: 471
PDF File Size: 19.47 Mb
ePub File Size: 3.37 Mb
ISBN: 962-5-80519-511-3
Downloads: 28502
Price: Free* [*Free Regsitration Required]
Uploader: Akinoshicage

Their core argument is that the anticommons emerges when the rights necessary to practice research are split up among a large number, and a large variety, of different researchers.

Help How to edit FAQ. This page was last modified biomedidal 11 Octoberat This essentially introduces a set of complex collective action problems beyond those introduced by patent licensing which they suggest may create an important barrier to scientific progress.

Theoretical and practical relevance: They argue that, “privatization can solve one anticom,ons but cause another. The article is often treated as argument against particular patents. Published in Science inHeller and Eisenberg frame their argument explicitly in terms of Hardin’s classic piece of The tragedy of the commons and applied to biomedical research although it has been used and cited as relevant more broadly.


The anticommons in biomedical research.

Can Patents Deter Innovation? The Anticommons in Biomedical Research

Privacy policy About AcaWiki Disclaimers. The article was also tested by Walsh et al. The metaphor of the anticommons has become a frequently cited in the areas of open innovation, arguments in favor of open science, and critiques of the patent system more generally.

New Recent Changes Featured Summaries. Heller and Eisenberg are reacting, in large part, to the growth of patenting within in biomedical science see Murray for more detail on case study of this in the area of mouse-research.

Heller and Eisenberg’s article has been cited more than 1, times in the last 12 years and has become a major article in the literature critical of patents in science. Retrieved from ” https: Eisenberg Can patents deter innovation? That said, the article seems to be somewhat missued by a number of “downstream” academics citing it.

Can patents deter innovation? The anticommons in biomedical research.

They use examples of patents on concurrent fragments which they suggest may be creating thickets and reach-through licensing agreements to make this point. They explain quite clearly that, “the tragedy of the anticommons refers to the more complex obstacles that arise when a user needs access to multiple patented inputs to create a single useful output. In fact, it’s argument is carefully crouched in terms anticommins the problems of patents in aggregate.


Views Read View form View source View history. They end by describing why different types of organizations i.

Can patents deter innovation? The anticommons in biomedical research.

In that sense, Murray and Stern’s article econometric article testing the hypothesis is a somewhat rough match for the theory offered. They argue that just as too much open access resarch an expendable public resource can create a tragedy of the commons, too much ownership — especially an intellectual domain — can create thickets that limit the progress of science more broadly.

Content is available under Creative Commons Attribution 3.

Back To Top